Date: 2011-09-29
Type of information: Licensing agreement
Compound: ebastine (Kestine®)
Company: Almirall (Spain) Nycomed (Switzerland)
Therapeutic area: Allergic diseases - Dermatological diseases - Immunological diseases
Type agreement: licensing
supply
Action mechanism: Ebastine is a second-generation non-sedating H1 receptor antagonist antihistamine that is administered once a day. It
Disease: allergic rhinitis, chronic idiopathic urticaria
Details: Almirall and Nycomed have signed a licensing and supply agreement for Almirall’s R&D antihistamine ebastine, under the trademark Kestine®, indicated for allergic rhinitis and chronic idiopathic urticaria, in China and other key emerging markets.
Under the terms of the agreement, Nycomed will have exclusive commercialisation rights for the existing Kestine® product in China. Additionally, Kestine® will be launched in Malaysia, Philippines, Singapore, Thailand and Indonesia, with Nycomed becoming marketing authorisation holder in these territories.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
